Welcome to the official InxMed website

EN CN



CONQUERING TREATMENT RESISTANCE OF TUMORS

We dedicate on developing innovative therapies targeting tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment resistance





OUR SCIENCE

Priming tumor microenvironment with regimen，killing cancer cells and consolidating treatment via specified therapy

Learn More

R&D PIPELINE

xin

Time of issue:2023-02-21 16:41:00

Asset	Modality / Target	Regimen	Indication
IN10018 Small molecular FAK inhibitor		+ PLD	PROC (double-blind, placebo controlled, randomized study)
		+ MEKi ± IO	IO-failed NRAS melanoma Uveal melanoma
		+ PLD ± IO	PROC, TNBC, HNSCC
		+ chemotherapy + IO	IO-failed NSCLC (randomized study)
		+ chemotherapy + IO bispecific	Pancreatic cancer
		+ KRAS^G12C inhibitor	KRAS^G12CCRC and NSCLC
		+3rd EGFR inhibitor	EGFR mutant NSCLC
OMTX705	ADC Targeting FAP	Mono / Combo	Solid Tumor
INES103	Antibody Target undisclosed	Combo	Solid Tumor
IN30718	ADC Target undisclosed	Mono	Solid Tumor
IN30728	ADC Target undisclosed	Mono	Solid Tumor
IN20019	Small molecular Target undisclosed	Mono	Solid Tumor

LATEST NEWS

Press Release

2023-10-25

InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023

NANJING, China, Oct 23, 2023 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome drug resistance for hard-to-treat solid tumors, announces that clinical data of Ifebemtinib (IN10018), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in platinum-resistant recurrent ovarian cancer （PROC）and triple-negative breast cancer（TNBC）has been presented at the 2023 European Society for Medical Oncology (ESMO) Congress taking place October 20-24 in Madrid，Spain.

2023-10-19

InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline

NANJING, China, Oct 19, 2023 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome treatment resistance for hard-to-treat solid tumors, is presenting preclinical data at 14th Annual World ADC Conference in San Diego regarding IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), to boost efficacy of ADCs, and IN30718，a First-in-Class cancer associated fibroblast (CAF) targeting ADC for high stroma tumors.

2023-08-30

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC

Nanjing, China, Aug 30, 2023 InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors，announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug) approval from China National Medical Products Administration (NMPA) recently.

Media Coverage

2022-03-17

BioWorld：Inxmed raises $50M to develop cancer therapy in the US, China

Inxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the U.S. and China. Inxmed plans to use the funds to invest in trials of IN-10018, bring more stroma-targeting candidates into clinic trials, and improve the firm’s R&D capabilities.

2019-06-20

Dialogue | interview with Dr. Wang Zaiqi, chairman of the Organizing Committee of the 5th dia China Pharmaceutical R & D Innovation Conference in 2009

In June 2019, New England magazine published the major research achievement of Tu youyou's team - "artemisinin resistance" treatment response plan. This is an important achievement of China in the field of global drug R & D. Benchmarking international, China's R & D of innovative drugs has attracted worldwide attention.

2019-07-29

Freehand character Wang Zaiqi: research and development of individualized therapeutic drugs with global influence

Dr. Wang Zaiqi will attend the global clinical research and development failure and success case analysis, the 96th activity of the same freehand brushwork forum for the third time, and make a special report - "the experience of using anti-PD-1 combined chemotherapy drugs in gastric cancer chemotherapy - excellent early trial data and disappointing phase 3 results. What have we learned?"

We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world

QUICK LINKS

CONTACT US

Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing

MESSAGE

   